Terapia uveitelor neinfecțioase: actualități și perspective

Lilia Dumbraveanu; Valeriu Cusnir; Doina Bobescu

doi:10.52556/2587-3873.2022.1(92).07

Treatment of noninfectious uveitis: news and perspectives

Authors

Lilia Dumbraveanu Nicolae Testemițanu State University of Medicine and Pharmacy https://orcid.org/0000-0001-8649-6489
Valeriu Cusnir Nicolae Testemițanu State University of Medicine and Pharmacy https://orcid.org/0000-0001-8222-5585
Doina Bobescu Nicolae Testemițanu State University of Medicine and Pharmacy https://orcid.org/0000-0002-8824-184X

DOI:

https://doi.org/10.52556/2587-3873.2022.1(92).07

Keywords:

uveitis, ocular inflammation, intravitreal therapy

Abstract

Uveitis is an eye disease characterized by inflammation of the vascular tunic. Patients often have visual impairment, which may result directly from damage to the structures of the uveal tract or may be due to side effects on nearby tissues. The etiopathogenic diagnosis and early treatment of uveitis prevent irreversible vision-threatening lesions caused by the intraocular inflammatory process and its complications, including cataracts, glaucoma and uveitic cystoid macular edema. Medication in non-infectious uveitis aims to suppress the immune system and intraocular inflammation, reduce recurrences and rehabilitate visual functions. Standard therapy includes corticosteroids, conventional immunomodulatory agents, and biological agents. In the long run, corticosteroids cause serious systemic and ocular side effects such as high blood pressure, diabetes, cataracts and glaucoma. Cytostatics and immunosuppressants may be considered in patients with systemic diseases such as sarcoidosis, rheumatoid arthritis, and juvenile idiopathic arthritis. This review article comes with useful information about the evolution of the treatment of non-infectious uveitis and the news in the field, which will be of real use for the clinician in daily practice. Lately, intravitreal therapy has become a favorite for most eye diseases, including non-infectious uveitis due to its effectiveness and better safety profile. Advances in molecular research have led to the development of new therapies in uveitis-biological agents that interfere with specific molecules that cause inflammation and tissue damage. Janus kinase inhibitors (JAKs) and biosimilar biological agents may present an alternative treatme option for patients with autoimmune ocular inflammation.

References

1. Thorne J.E., Suhler E., Skup M. et al. Prevalence of Noninfectious Uveitis in the United States: A Claims-Based Analysis. JAMA Ophthalmol. 2016;134(11):1237-1245. Disponibil pe: https://doi.org/10.1001/jamaophthalmol.2016.3229

2. Zierhut M., de MDS., Gupta V., Pavesio C., Nguyen Q.D., Chee S.P., Agarwal R. Konsenserfahrung von International Uveitis Study Group, Intraocular Inflammation Society und Foster Ocular Inflammation Society zur Uveitis in der Zeit der COVID-19-Infektion [Evolving Consensus of International Uveitis Study Group, Intraocular Inflammation Society, and Foster Ocular Inflammation Society with Uveitis in the Time of COVID-19 Infection]. Klin Monbl Augenheilkd. 2020 Sep;237(9):1124-1128. German. Disponibil pe: Epub 2020 Aug 14. PMID: 32797464; PMCID: PMC7516354. https://doi.org/10.1055/a-1201-3277

3. Miserocchi E., Modorati G., Berchicci L., Pontikaki I., Meroni P., Gerloni V. (2016) Long-term treatment with rituximab in severe juvenile idiopathic arthritisassociated uveitis. Br J Ophthalmol 100(6):782-786. Disponibil pe: https://doi.org/10.1136/bjophthalmol-2015-306790

4. Abu El-Asrar A.M., Dheyab A., Khatib D., Struyf S., Van Damme J., Opdenakker G. (2020) Efficacy of B cell depletion therapy with rituximab in refractory chronic recurrent uveitis associated with Vogt-KoyanagiHarada disease. Ocul Immunol Inflamm 27:1-8. https://doi.org/10.1080/09273948.2020.1820531

5. Babu K., Murthy G.J., Murthy K.R. (2020) Uveitis, retinal vasculitis, and loss of accommodation as sole manifestations of demyelinating disease: a case report. Indian J Ophthalmol 68(9):2007-2009. Disponibil pe: https://doi.org/10.4103/ijo.IJO_2017_19

6. McHarg M., Young L., Kesav N. et al. Practice patterns regarding regional corticosteroid treatment in noninfectious Uveitis: a survey study. J Ophthal Inflamm Infect 12, 3 (2022). Disponibil pe: https://doi.org/10.1186/s12348-021-00281-z

7. Joseph R.M., Hunter A.L., Ray D.W., Dixon W.G. Systemic glucocorticoid therapy and adrenal insufficiency in adults: a systematic reviewSemin Arthritis Rheum, 46 (2016), pp. 133-141. https://doi.org/10.1016/j.semarthrit.2016.03.001

8. Solebo A.L., Rahi J.S., Dick A.D., Ramanan A.V., Ashworth J., Edelsten C., Members of the POIG Uveitis Delphi Group (2020). Areas of agreement in the management of childhood non-infectious chronic anterior uveitis in the UK. Br J Ophthalmol 104(1):11-16. Disponibil pe:

https://doi.org/10.1136/bjophthalmol-2018-313789

9. Takeuchi M., Kanda T., Kaburaki T., Tanaka R., Namba K., Kamoi K., Maruyama K., Shibuya E., Mizuki N. (2019) Real-world evidence of treatment for relapse of noninfectious uveitis in tertiary centers in Japan: a multicenter study. Medicine (Baltimore) 98(9):e14668. Disponibil pe: https://doi.org/10.1097/MD.0000000000014668

10. Writing Committee for the Multicenter Uveitis Steroid Treatment Trial Follow-up Study Research Group, Kempen J.H., Altaweel M.M., Holbrook J.T., Sugar E.A., Thorne J.E. et al. Association between long-lasting intravitreous fluocinolone acetonide implant vs systemic anti-inflammatory therapy and visual acuity at 7 years among patients with intermediate, posterior, or panuveitis. JAMA, 317 (2017), pp. 1993-2005. https://doi.org/10.1001/jama.2017.5103

11. Thorne J.E., Sugar E.A., Holbrook J.T., Burke A.E., Altaweel M.M., Vitale A.T., Acharya N.R., Kempen J.H., Jabs D.A., Multicenter Uveitis Steroid Treatment Trial Research Group (2019). Periocular triamcinolone vs. intravitreal triamcinolone vs. intravitreal dexamethasone implant for the Treatment of Uveitic macular edema: the PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) trial. Ophthalmology 126(2):283-295. Disponibil pe: https://doi.org/10.1016/j.ophtha.2018.08.021

12. Nguyen Q.D., Merrill P.T., Clark W.L., Banker A.S., Fardeau C., Franco P. et al. Intravitreal sirolimus for noninfectious uveitis: a phase III Sirolimus Study Assessing Double-masKed Uveitis TReAtment (SAKURA) Ophthalmology, 123 (2016), pp. 2413-2423. https://doi.org/10.1016/j.ophtha.2016.07.029

13. Rivera-Grana E., Siak J., Rosenbaum J.T. (2018). Use of biologic response modifiers for the management of ocular inflammatory conditions. Indian J Rheumatol 13(4):259. https://doi.org/10.4103/injr.injr_83_18

14. Touhami S., Diwo E., Sève P., Trad S., Bielefeld P., Sène D., Abad S., Brézin A., Quartier P., Paut I.K. et al. Expert opinion on the use of biological therapy in non-infectious uveitis. Expert Opin. Biol. Ther. 2019;19:477-490. Disponibil pe: https://doi.org/10.1080/14712598.2019.1595578

15. Dick A.D., Rosenbaum J.T., Al-Dhibi H.A., Belfort R., Jr., Brézin A.P., Chee S.-P., Davis J.L., Ramanan A.V., Sonoda K.-H., Carreño E. et al. Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis. Ophthalmology. 2018;125:757-773. Disponibil pe: https://doi.org/10.1016/j.ophtha.2017.11.017

16. Kempen J.H., Daniel E., Gangaputra S., Dreger K., Jabs D.A., Kacmaz R.O., Pujari S.S., Anzaar F., Foster C.S., Helzlsouer K.J. et al. Methods for Identifying Long

Downloads

PDF (Romanian)

Published

2026-04-20

Issue

No. 1(92) (2022)

Section

Articles

License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

How to Cite

[1]

Dumbraveanu, L. et al. 2026. Treatment of noninfectious uveitis: news and perspectives. Public Health Economy and Management in Medicine. 1(92) (Apr. 2026), 42–50. DOI:https://doi.org/10.52556/2587-3873.2022.1(92).07.

Download Citation

Most read articles by the same author(s)

Adrian Cociug, Olga Macagonova, Lilia Dumbraveanu, Valeriu Cusnir, Viorel Nacu, Innovative technological systems in cornea collection and processing , Public Health Economy and Management in Medicine: No. 1(92) (2022)
Valeriu Cusnir, Vadim Popovici, Doina Bobescu, Cusnir Cusnir, Irina Dascov, Side effects of intraocular tumors in the development of secondary glaucoma , Public Health Economy and Management in Medicine: No. 1(92) (2022): Supliment. Conferința științifico-practică a Oftalmologilor din municipiul Chișinău cu participare națională și internațională, ediția a VII-a „Actualități în oftalmologie”
Nicoale Bobescu, Valeriu Cusnir, Lilia Dumbraveanu, Cornelia Ceban, Predictive factors of age-related macular degeneration evolution in response to anti-vascular endothelial growth factor therapy , Public Health Economy and Management in Medicine: No. 1(92) (2022)
Doina Bobescu, Valeriu Valeriu, Lilia Dumbraveanu, Etiopathogenesis of inflammatory glaucoma. Treatment aspects , Public Health Economy and Management in Medicine: No. 1(92) (2022)
Ludmila Suratel, Valeriu Cusnir, Daria Stratan, Incidence of pseudoexfoliative syndrome in cataract and primary open-angle glaucoma , Public Health Economy and Management in Medicine: No. 1(92) (2022): Supliment. Conferința științifico-practică a Oftalmologilor din municipiul Chișinău cu participare națională și internațională, ediția a VII-a „Actualități în oftalmologie”
Cusnir Cusnir, Dumbraveanu Dumbraveanu, Rodica SŞevciuc, Aurel Rusu, Ludmila Suratel, Doina Bobescu, Valeriu Cusnir, Nicoale Bobescu, Irina Iorga, Vadim Popovici, Primary glaucoma in adults. National Clinical Protocol , Public Health Economy and Management in Medicine: No. 1(92) (2022): Supliment. Conferința științifico-practică a Oftalmologilor din municipiul Chișinău cu participare națională și internațională, ediția a VII-a „Actualități în oftalmologie”
Vitalie Procopciuc, Valeriu Cusnir, Viorel Nacu, Amniotic membrane transplantation in the management of cornal ulcers refractory to conventional treatment , Public Health Economy and Management in Medicine: No. 1(92) (2022): Supliment. Conferința științifico-practică a Oftalmologilor din municipiul Chișinău cu participare națională și internațională, ediția a VII-a „Actualități în oftalmologie”
Lilia Dumbraveanu, Codrean Rata, Optical-refractive treatment of patients with computer vision syndrome (svc ) and associated asthenopia , Public Health Economy and Management in Medicine: No. 1(92) (2022): Supliment. Conferința științifico-practică a Oftalmologilor din municipiul Chișinău cu participare națională și internațională, ediția a VII-a „Actualități în oftalmologie”
Lilia, Valeriu Cusnir, Daria Stratan, Gheorghe Manolache, Pages of history (teachers and disciples) , Public Health Economy and Management in Medicine: No. 1(92) (2022): Supliment. Conferința științifico-practică a Oftalmologilor din municipiul Chișinău cu participare națională și internațională, ediția a VII-a „Actualități în oftalmologie”
Veronica Gotisan, Valeriu Cusnir, Lilia Dumbraveanu, Nicoleta Tulea, Sindromul de ochi uscat în boala Sjogren , Public Health Economy and Management in Medicine: No. 1(92) (2022): Supliment. Conferința științifico-practică a Oftalmologilor din municipiul Chișinău cu participare națională și internațională, ediția a VII-a „Actualități în oftalmologie”

1 2 3 > >>

Treatment of noninfectious uveitis: news and perspectives

Authors

DOI:

Keywords:

Abstract

References

Downloads

Published

Issue

Section

License

How to Cite

Most read articles by the same author(s)

Similar Articles

Language

issn

oa cc-by-nc-sa

road-issn

crossref member

ibn